Wells Fargo's stock up on reported progress on its biggest outstanding regulatory issue
By Steve Gelsi
Bank submits overhaul to the U.S. Federal Reserve in move to lift seven-year-old asset cap
Wells Fargo & Co.'s stock rose 3.5% on Thursday after a report that the bank has submitted a third-party review of its risk and control efforts as part of its move to lift a seven-year-old asset cap.
The asset cap of $1.95 trillion imposed in 2017 remains the most severe of the regulatory actions faced by Wells Fargo (WFC) following actions including the creation of fake bank accounts and other scandals involving how the bank dealt with consumers.
The bank has handed in a review to the U.S. Federal Reserve, the report said, citing people familiar with the bank.
A spokesperson for Wells Fargo declined to comment. The Federal Reserve did not comment.
Wells Fargo officials expect the asset cap to remain in place at least into 2026, but an exact timeline remains uncertain, the report said.
Also read: Analysts shrug off Wells Fargo's latest snag with regulators, but note that others remain
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-26-24 1116ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks